| Literature DB >> 35197413 |
Mahmoud Baakhtari1,2,3, Noriko Imaizumi2, Tetsuo Kida2, Tenya Yanagita2, Amany Ramah1,4, Parnian Ahmadi1,3, Naoya Takebe5, Yohei Iwamoto5, Kenji Korosue5, Nao Tsuzuki6, Masahiro Yasuda1,2.
Abstract
High-intensity exercise and competition are associated with depressed immune function. Young horses, which participate in high-intensity exercise and competitions, are at increased risk for the development of infectious disease due to depression of immune function. The effects of branched-chain amino acid (BCAA) supplementation on the immune status of young racing horses were evaluated, determining whether BCAA might help to avoid or reduce immune suppression during exercise and competitions. Twenty horses (10 male and 10 female) were treated with BCAA supplementation; another twenty untreated horses (10 male and 10 female) constituted control group. Peripheral blood was collected from each animal and evaluated for lymphocyte subsets, phagocytosis analysis of monocytes and granulocytes, lymphocyte proliferative response, and expression of cytokine-encoding messenger ribonucleic acids (mRNAs). The numbers of CD4+, CD8+, and major histocompatibility complex (MHC) class II+ cells in females of the treated group were significantly higher than those in females of the control group. The lymphocyte proliferative response in female of the treated group also was significantly higher than that in females of the control group. In addition, expression of mRNAs encoding interleukin-1β (IL-1β) and interferon-γ (IFN-γ) in females of the treated group was significantly higher than that in females of the control group. There were no significant differences between males of the treated and control groups. The results of this study indicated the positive effects of BCAA supplementation in counteracting immunosuppression in young female racing horses during and following high-intensity exercise.Entities:
Keywords: branched-chain amino acid; immune status; young racing horse
Mesh:
Substances:
Year: 2022 PMID: 35197413 PMCID: PMC9096041 DOI: 10.1292/jvms.21-0529
Source DB: PubMed Journal: J Vet Med Sci ISSN: 0916-7250 Impact factor: 1.267
Exercise protocol during the period of study
| Month | Walking (m) | Trot (m) | Gallop (m) | Total (m) | Walking machine | Note | |
|---|---|---|---|---|---|---|---|
| October | Middle | 1,600 | 2,000 | 1,000 | 4,600 | ||
| Late | 1,600 | 2,000 | 1,600 | 5,200 | |||
| November | Early | 1,600 | 2,000 | 1,600 | 5,200 | ||
| Middle | 1,600 | 2,000 | 2,000 | 5,600 | |||
| Late | 1,600 | 2,000 | 2,400 | 6,000 | |||
| December | Early | 2,000 | 2,000 | 2,800 | 6,800 | 3,000 m for 30 min (6 km/hr) | Speed up to 600 m/min |
| Late | 2,000 | 2,000 | 2,800 | 6,800 | |||
| January | Early | 2,000 | 1,200 | 2,000 | 5,200 | Speed up to 667 m/min | |
| Late | 2,000 | 1,200 | 2,400 | 5,600 | |||
| February | Early | 2,000 | 1,200 | 2,000 | 5,200 | Speed up to 800 m/min | |
| Late | 2,000 | 1,200 | 2,400 | 5,600 | |||
| March | Early | 2,000 | 1,200 | 2,000 | 5,200 | Speed up to 857 m/min | |
| Late | 2,000 | 1,200 | 2,400 | 5,600 | |||
| April | Early | 2,000 | 1,200 | 2,000 | 5,200 | Speed up to 900 m/min | |
| Late | 2,000 | 1,200 | 2,400 | 5,600 | |||
Primer sequences used for real-time PCR
| Gene | Primer | Sequences | Accession number | Length(base pairs) |
|---|---|---|---|---|
| GAPDH | F | CTCCTTCTGCTGATGCCCCAA | NM_001163856 | 155 |
| R | GAGTCCCTCCACGATGCCAAA | |||
| IL-1 β | F | ACAAGACTTTCAAACATGCCAT | NM_001317261 | 180 |
| R | TGGCTGCATCACATACATAACCT | |||
| IL-4 | F | CTTACTAGCATGTACCAGCAAC | AF305617 | 143 |
| R | CAGCAAAGGCATCCGCTAC | |||
| IL-6 | F | CACATTAAGTACATCCTCGGCAA | NM_001082496 | 179 |
| R | ATTTTCATCAGGCAGGTCTC | |||
| IL-8 | F | GCATCAAGACGCACTCCAA | AY184956 | 160 |
| R | ACAATAATCTGCACCCACT | |||
| IL-12p40 | F | GCCATTCTCACCTGCTGCTTC | Y11129 | 141 |
| R | GCCACCAGCATGTGAAACGTC | |||
| IFN- γ | F | AAAATAATTCAGAGCCAAATCG | D28520 | 172 |
| R | CCGGAATCTGAATCAGCTTT | |||
| TNF- α | F | AATGCCTTCCAGTCAATCAACCC | NM_001081819 | 172 |
| R | TGTCTGTCAGCTTCACGCCATT |
Fig. 1.Effect of branched-chain amino acid (BCAA) on male and female CD4 cell population. The treated group was fed by BCAA supplementation daily and the untreated group was considered a control. The data are presented as mean ± SD. Letters (b: P<0.01 vs. control) indicate significant differences.
Fig. 2.Effect of branched-chain amino acid (BCAA) on male and female CD8 cell populations. The treated group was fed by BCAA supplementation daily and the untreated group was considered a control. The data are presented as mean ± SD. Letters (a: P<0.05 vs. control) indicate significant differences.
Fig. 3.Effect of branched-chain amino acid (BCAA) on male and female major histocompatibility complex (MHC) class II cell populations. The treated group was fed by BCAA supplementation daily and the untreated group was considered a control. The data are presented as mean ± SD. Letters (b: P<0.01 vs. control) indicate significant differences.
Fig. 4.Effect of branched-chain amino acid (BCAA) on male and female lymphocyte proliferative response to concanavalin A (Con A). The stimulation index was evaluated for the treated group, fed by BCAA supplementation daily, and for the untreated group, which was considered a control. The data are presented as mean ± SD. Letters (a: P<0.05 vs. control, b: P<0.01 vs. control) indicate significant differences.
Fig. 5.Effect of branched-chain amino acid (BCAA) on male and female phagocytic index for granulocytes. The treated group was fed by BCAA supplementation daily and the untreated group was considered a control. The data are presented as mean ± SD.
Fig. 6.Effect of branched-chain amino acid (BCAA) on male and female phagocytic index for monocytes. The treated group was fed by BCAA supplementation daily and the untreated group was considered a control. The data are presented as mean ± SD.
Fig. 7.Effect of branched-chain amino acid (BCAA) on expression (in April for male and female) of mRNAs encoding interferon-γ (IFN-γ), interleukin-1β (IL-1β), IL-4, IL-6, IL-8, IL-12, and tumor necrosis factor-α (TNF-α). The treated group was fed by BCAA supplementation daily and the untreated group was considered a control. Expression levels were measured by real-time PCR. The data are presented as mean ± SD. Letters (a: P<0.05 vs. control) indicate significant differences.